Page 2 - தொற்று நோய் சமூகம் ஆஃப் அமெரிக்கன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Delta COVID-19 variant is way more dangerous than original strain, expert says
fox10phoenix.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fox10phoenix.com Daily Mail and Mail on Sunday newspapers.
Delta COVID-19 variant is way more dangerous than original strain, expert says
fox7austin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fox7austin.com Daily Mail and Mail on Sunday newspapers.
Zika Vaccine Candidate Shows Promise in Phase 1 Trial
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
President Donald Trump, former New Jersey Gov. Chris Christie and former New York City Mayor Rudy Giuliani all received monoclonal antibodies when they were treated for COVID-19.
And despite having risk factors such as age and weight that put them at risk of getting very sick, they recovered quickly, though Christie spent a week in intensive care.
They all credit monoclonal antibodies.
But only a fraction of those doses have reached the people who could benefit from them, Health and Human Services Secretary Alex Azar said Monday.
The reason is a mix of science and politics,
with some logistical and staffing challenges thrown in.
Monoclonal antibodies may have helped Donald Trump recover from COVID-19, but many others aren t getting them Karen Weintraub, USA TODAY
Replay Video UP NEXT
President Donald Trump, former New Jersey Gov. Chris Christie and former New York City Mayor Rudy Giuliani all received monoclonal antibodies when they were treated for COVID-19.
And despite having risk factors such as age and weight that put them at risk of getting very sick, they recovered quickly, though Christie spent a week in intensive care.
They all credit monoclonal antibodies.
The reason is a mix of science and politics, with some logistical and staffing challenges thrown in.